About Biocorrx (OTCMKTS:BICX)
BioCorRx, Inc., formerly Fresh Start Private Management, Inc., is a holding company. The Company is an addiction healthcare solutions company operating in Santa Ana, California. The Company, through its subsidiary, Fresh Start Private, Inc., provides alcoholism and opioid treatment program. It offers a medication-assisted treatment program that combines non-addictive medication coupled with psycho-social counseling. It also distributes and licenses the BioCorRx Recovery Program for alcoholism and opioid addiction treatment. The BioCorRxO Recovery Program consists of over two parts, which include an implant, administered by a licensed physician, of a compounded formulation of the drug, Naltrexone (implanted under the skin) (the Implant), which reduces alcohol cravings over a period of time, and a structured, intensive one on one counseling program developed by it. It offers BioCorRx Recovery Program in over 10 locations, including California, Arizona, Atlanta, Illinois and others.
Industry, Sector and Symbol
Trailing P/E Ratio-1.41168166578437
Forward P/E RatioN/A
Sales & Book Value
Price / Sales83.40
Price / CashN/A
Book Value($0.05) per share
Price / Book-4.80
Return on EquityN/A
Return on Assets-150.00%
Biocorrx (OTCMKTS:BICX) Frequently Asked Questions
What is Biocorrx's stock symbol?
Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."
How were Biocorrx's earnings last quarter?
Biocorrx Inc (OTCMKTS:BICX) posted its earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $0.17 million for the quarter. View Biocorrx's Earnings History.
When will Biocorrx make its next earnings announcement?
Who are some of Biocorrx's key competitors?
Some companies that are related to Biocorrx include Checkpoint Therapeutics (CKPT), Evogene (EVGN), Arcturus Therapeutics (ARCT), Vermillion (VRML), CytoDyn (CYDY), ProQR Therapeutics (PRQR), Nuvectra (NVTR), ADMA Biologics (ADMA), Medicure (MCUJF), Invuity (IVTY), Alimera Sciences (ALIM), Trillium Therapeutics (TRIL), Gemphire Therapeutics (GEMP), KemPharm (KMPH), ContraFect (CFRX), BioLife Solutions (BLFS), Medgenics (GNMX) and Edap Tms (EDAP).
Who are Biocorrx's key executives?
Biocorrx's management team includes the folowing people:
- Brady J. Granier, President, Chief Executive Officer, Director (Age 43)
- Lourdes Felix, Chief Financial Officer, Chief Operating Officer, Treasurer, Director (Age 48)
- Tom Welch, Director - Operations
- Kent Emry, Director (Age 47)
How do I buy Biocorrx stock?
Shares of Biocorrx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocorrx's stock price today?
One share of Biocorrx stock can currently be purchased for approximately $0.24.
How big of a company is Biocorrx?
Biocorrx has a market capitalization of $52.30 million and generates $700,000.00 in revenue each year. The company earns $-5,900,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.
How can I contact Biocorrx?
Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]
MarketBeat Community Rating for Biocorrx (BICX)MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biocorrx (OTCMKTS:BICX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Biocorrx (OTCMKTS:BICX) Earnings History and Estimates Chart
Biocorrx (OTCMKTS BICX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/12/2018|| || || || || || || || |
|11/17/2016||Q3 2016||($0.02)||$0.17 million||View||N/A|
Biocorrx (OTCMKTS:BICX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Biocorrx (OTCMKTS:BICX)
No dividend announcements for this company have been tracked by MarketBeat.com
Biocorrx (OTCMKTS BICX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.85%
Biocorrx (OTCMKTS BICX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/27/2015||Jorge Andrade Jr||Director||Sell||125,000||$0.06||$7,500.00|| |
|2/26/2015||Jorge Andrade Jr||Director||Sell||245,000||$0.05||$12,250.00|| |
|2/23/2015||Jorge Andrade Jr||Director||Sell||215,000||$0.06||$12,900.00|| |
|2/17/2015||Jorge Andrade Jr||Director||Sell||90,000||$0.08||$7,200.00|| |
|2/10/2015||Jorge Andrade Jr||Director||Sell||60,000||$0.09||$5,400.00|| |
|10/28/2014||Jorge Andrade Jr||Director||Sell||25,000||$0.09||$2,250.00|| |
|10/13/2014||Jorge Andrade Jr||Director||Sell||80,000||$0.09||$7,200.00|| |
|10/7/2014||Jorge Andrade Jr||Director||Sell||40,000||$0.11||$4,400.00|| |
|10/1/2014||Jorge Andrade Jr||Director||Sell||30,000||$0.13||$3,900.00|| |
|9/29/2014||Jorge Andrade Jr||Director||Sell||170,000||$0.10||$17,000.00|| |
|9/22/2014||Jorge Andrade Jr||Director||Sell||130,000||$0.10||$13,000.00|| |
|9/15/2014||Jorge Andrade Jr||Director||Sell||90,000||$0.10||$9,000.00|| |
|9/8/2014||Jorge Andrade Jr||Director||Sell||95,000||$0.11||$10,450.00|| |
|8/22/2014||Jorge Andrade Jr||Director||Sell||100,000||$0.13||$13,000.00|| |
|8/14/2014||Jorge Andrade Jr||Director||Sell||300,000||$0.14||$42,000.00|| |
Biocorrx (OTCMKTS BICX) News Headlines
|BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic|
finance.yahoo.com - January 2 at 10:38 AM
|BioCorRx Recovery Program Used in Lieu of Conviction in Ohio|
finance.yahoo.com - December 22 at 11:02 AM
|BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102|
finance.yahoo.com - December 19 at 10:52 AM
|BioCorRx Enters Agreement with National Institute on Alcohol Abuse and Alcoholism|
finance.yahoo.com - December 14 at 4:37 PM
|UPDATE: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery Program|
finance.yahoo.com - December 12 at 4:20 PM
|BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery|
finance.yahoo.com - December 12 at 11:27 AM
|BioCorRx's (BICX) CEO Brady Granier on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 18 at 1:14 AM
|BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant|
finance.yahoo.com - November 16 at 9:34 AM
|BioCorRx Provides Business Update for the Third Quarter of 2017|
finance.yahoo.com - November 16 at 9:34 AM
|BioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and Virginia|
finance.yahoo.com - October 25 at 5:56 PM
|BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia|
finance.yahoo.com - October 19 at 5:07 PM
|BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction|
finance.yahoo.com - October 17 at 5:20 PM
|BioCorRx To Launch New Weight Management Program|
finance.yahoo.com - October 5 at 8:04 AM
|BioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone Implant - Baystreet.ca|
www.baystreet.ca - September 29 at 8:44 AM
|BioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone Implant|
www.baystreet.ca - September 28 at 10:34 AM
|BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder|
finance.yahoo.com - September 12 at 4:49 PM
|BioCorRx to Exhibit at CASAM Conference in San Francisco, California|
finance.yahoo.com - August 21 at 4:31 PM
|BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017|
finance.yahoo.com - August 15 at 5:24 PM
|BioCorRx Schedules Second Quarter 2017 Business Update & Earnings Conference Call|
finance.yahoo.com - August 11 at 5:01 PM
|Serrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los Angeles|
finance.yahoo.com - July 31 at 4:31 PM
|BioCorRx Announces EnLite(TM) Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio|
finance.yahoo.com - July 25 at 4:24 PM
|BioCorRx Announces First Addiction Treatment Center in South Florida to Implement the BioCorRx Program|
finance.yahoo.com - July 21 at 6:11 PM
|BioCorRx to Exhibit at ASAM Conference in Dallas, Texas|
finance.yahoo.com - July 6 at 4:07 PM
|BioCorRx Inc.: BioCorRx to Present at the 2017 Marcum Microcap Conference|
www.finanznachrichten.de - June 7 at 4:13 PM
|BIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - February 8 at 4:04 PM
|21st Century Cures Act Hopes To Reduce $41 Billion Annual Cost Of Opioid Treatments|
seekingalpha.com - January 22 at 3:53 PM
|BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - August 3 at 12:30 PM
|BIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statemen|
biz.yahoo.com - May 20 at 5:05 PM
|BIOCORRX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - April 18 at 4:13 PM
|BIOCORRX INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - April 14 at 2:55 PM
Biocorrx (OTCMKTS:BICX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Biocorrx (OTCMKTS BICX) Stock Chart for Saturday, January, 20, 2018